Last reviewed · How we verify
Glargine Basal-Bolus Therapy
At a glance
| Generic name | Glargine Basal-Bolus Therapy |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD) (PHASE4)
- Degludec Glargine U300 Hospital Study (NA)
- To Evaluate add-on Effect of Nisha-Amalaki Tablets Along With Insulin on Glycemic Control in Type 1 Diabetes Patients (RCTNA) (NA)
- Effect of the Use of Continuous Glucose Monitoring Versus Standard Glycemic Control in Hospitalized Patients with Type 2 Diabetes. (NA)
- Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients (PHASE4)
- The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins (PHASE4)
- Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glargine Basal-Bolus Therapy CI brief — competitive landscape report
- Glargine Basal-Bolus Therapy updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI